Showing 1 - 6 of 6
DOI: 10.2165/0019053-200826100-00009
Persistent link: https://www.econbiz.de/10004997788
While the EuroQOL instrument (EQ-5D) is being considered and used in clinical trials in the United States and Canada, and in large international multicentre studies, population weights for the instrument have never been established in North America. The primary purpose of this investigation was...
Persistent link: https://www.econbiz.de/10005404803
With the advent of highly active antiretroviral therapy (HAART), HIV-infected patients are living longer and are concerned not only with a treatment's ability to extend their life but also with the quality of the life they are able to lead. Regulatory authorities are also paying closer attention...
Persistent link: https://www.econbiz.de/10005590447
Uncertainty in the decision-making process for reimbursement of health technologies could be reduced if additional information were available. Although methods to evaluate the monetary value of the uncertainty have been previously described, an economic evaluation of alternative methods to...
Persistent link: https://www.econbiz.de/10005590472
We report results from the first randomization of a regulatory reform in the health sector. The reform established minimum quality standards for patient safety, an issue that has become increasingly salient following the Ebola and COVID-19 epidemics. In our experiment, all 1348 health facilities...
Persistent link: https://www.econbiz.de/10014287304
Governments in many low- and middle-income countries are developing health insurance products as a complement to tax-funded, subsidized provision of health care through publicly operated facilities. This paper discusses two rationales for this transition. First, health insurance would boost...
Persistent link: https://www.econbiz.de/10014247916